Savara (SVRA) Posts Earnings Results, Misses Expectations By $0.03 EPS

Savara (NASDAQ:SVRA) posted its quarterly earnings data on Wednesday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03), Morningstar.com reports.

Shares of SVRA traded up $0.95 on Thursday, reaching $10.77. The company’s stock had a trading volume of 114,155 shares, compared to its average volume of 190,424. The company has a current ratio of 10.30, a quick ratio of 10.30 and a debt-to-equity ratio of 0.16. The company has a market cap of $335.85 million, a price-to-earnings ratio of -6.12 and a beta of -0.06. Savara has a 12-month low of $8.41 and a 12-month high of $17.19.

In related news, CFO David L. Lowrance sold 18,480 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total value of $170,385.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 6.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its holdings in Savara by 22.6% during the first quarter. Northern Trust Corp now owns 58,530 shares of the company’s stock valued at $539,000 after purchasing an additional 10,779 shares in the last quarter. BlackRock Inc. lifted its holdings in Savara by 39.2% during the first quarter. BlackRock Inc. now owns 695,269 shares of the company’s stock valued at $6,396,000 after purchasing an additional 195,757 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Savara during the first quarter valued at approximately $307,000. UBS Group AG lifted its holdings in Savara by 1,012.8% during the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock valued at $133,000 after purchasing an additional 13,248 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in Savara by 1,161.8% during the first quarter. Millennium Management LLC now owns 522,897 shares of the company’s stock valued at $4,811,000 after purchasing an additional 481,456 shares in the last quarter. 41.84% of the stock is currently owned by institutional investors.

SVRA has been the topic of a number of research reports. Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the stock a “buy” rating in a report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Savara in a report on Friday, August 10th. Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. Finally, BidaskClub downgraded shares of Savara from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.80.

COPYRIGHT VIOLATION NOTICE: “Savara (SVRA) Posts Earnings Results, Misses Expectations By $0.03 EPS” was posted by WKRB News and is owned by of WKRB News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/09/savara-svra-posts-earnings-results-misses-expectations-by-0-03-eps.html.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Recommended Story: Understanding Stock Ratings

Earnings History for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply